Array BioPharma wants to offer sufferers of cancer, inflammatory, and metabolic diseases a multitude of treatment options. The development-stage company has seven wholly-owned programs in its development pipeline. Candidates include therapies for solid tumors (ARRY-543), arthritis (ARRY-162), breast cancer (ARRY-380), and type 2 diabetes (ARRY-403). Array also out-licenses some drug programs to AstraZeneca and Genentech; ARRY-886, developed with AstraZeneca, is in clinical trials for melanoma. Array's agreement with Genetech includes five candidates in various stages of development for the treatment of cancer. The company also has R&D agreements with Amgen, InterMune, Celgene, and others.